Bone Marrow Transplant For Sickle Cell Disease

Almost everybody else on a transplant ward is there because the alternative was dying soon. Sickle cell disease is the exception, and that changes the whole calculation.

Across 1,000 patients given a transplant from a matched sibling, five year event free survival came out at 91.4 percent and five year overall survival at 92.9 percent.

The transplant nobody is forced into

A patient with acute leukemia arrives at a transplant decision with the alternative already decided for them. Sickle cell disease does not work like that. Somebody with sickle cell disease can live for decades. They can work, raise children, and go years between the episodes that put them in hospital. The disease damages organs quietly across that whole time and it shortens life, and none of that removes the fact that a patient facing this decision is usually walking, talking and reasonably well on the day they are asked to consider it. That is the situation nobody else on the ward is in, and it turns the transplant question into something different from every other page in this section, because the trade is a slow harm you already know, against an acute risk taken on a date you choose, in exchange for the slow harm stopping.

Hold that framing through everything below. A number that looks good for a leukemia transplant may not be good enough here, because the comparison is not death within the year but a life with the disease, which is the thing being given up as well as the thing being escaped. Nobody in this position is being rescued from anything. They are choosing, and that is harder.

What the disease does if nothing changes

Setting the alternative out honestly is the first half of the decision, and it is frequently skipped. A natural history study followed 3,764 patients from birth up to the age of 66, and median age at death was 42 years for men with sickle cell anemia against 48 years for women. Half of the patients with sickle cell anemia survived past their fifties. And 33 percent of the adult deaths happened during an acute pain crisis, a chest syndrome or a stroke, in patients who had no overt chronic organ failure at the time, which means a third of those deaths arrived in people who were not visibly failing. Those figures predate several of the treatments now in routine use and they remain the clearest description available of what the disease does when it is left to run. Read the second figure again. A third of the adult deaths came in people who looked well until the week they died.

• Pain crises, which patients describe first and which drive most of the admissions.
• Stroke, which in children arrives without warning and drives the screening program described further down this page, where a single trial changed how it is managed.
• Acute chest syndrome, meaning a lung crisis that is among the commonest causes of death in this disease.
• Silent organ damage, meaning kidney, lung, heart, eye, bone and brain injury accumulating across decades without producing symptoms until late.

On stroke there is a trial that settled the question. 130 children with abnormal transcranial Doppler results were assigned either to regular transfusion or to standard care. The standard care group had ten cerebral infarctions and one hemorrhage, while the transfusion group had one infarction. That 92 percent reduction ended the trial early, and it established that a scan can identify children at high risk before anything has happened to them.

What the alternatives already achieve

Any transplant has to beat what is already available, and what is already available is better than it was.

The transfusion route, and what it costs

Regular transfusion prevents strokes and suppresses the disease, and it loads the body with iron that has nowhere to go. A study of 271 children with sickle cell disease on chronic transfusion mapped that loading against the standard blood test used to follow it, and found that most patients with a ferritin between 750 and 1,500 carried an iron burden of 25 to 100 milligrams per kilogram, which was 72.8 percent of those observations. Iron chelation removes it, works, and is a daily obligation for years with its own side effects and its own adherence problem. So the honest comparison sets a transplant against a drug that halves the crises, or against transfusion and chelation taken for life. Both alternatives share one feature the transplant does not. They require the patient to keep doing something, every day, for the rest of their life, and adherence across decades is where both of them quietly fail.

The result with a matched brother or sister

Good figures come from this situation, and it applies to a minority of patients.

A separate national series of 87 patients transplanted between 1988 and 2004 shows how the technique moved. Graft rejection ran at 22.6 percent before antithymocyte globulin was added to the conditioning and fell to 3 percent afterward, while overall survival across the whole series was 93.1 percent and event free survival 86.1 percent, while among the 44 patients transplanted after January 2000 event free survival reached 95.3 percent. Older figures in the literature therefore understate what a modern regimen does, and the improvement came from a change in conditioning rather than from anything dramatic. Roughly one patient in four has a sibling who matches, and the rest of this page is about what happens to the other three. That ratio is the single most useful thing a family can resolve early. Typing the siblings takes one blood test each and a few weeks, and it converts an open question into a closed one. Do it before anybody needs an answer.

Adults, and the gentler conditioning

Full intensity conditioning in an adult with years of organ damage behind them was, for a long time, the reason adults were not offered this at all. One study enrolled 30 adults with a severe sickle cell phenotype and used a nonmyeloablative regimen, meaning conditioning designed to make room for the donor cells without destroying the marrow outright, and twenty six of the 30, which is 87 percent, had long term stable donor engraftment with no acute and no chronic graft versus host disease. There was no transplant related mortality in the series. Mean annual hospitalization fell from 3.23 in the year before the transplant to 0.11 by the third year after it. That last figure is the one patients recognize, because it describes the thing the disease actually does to a life.

• Nonmyeloablative conditioning is gentler on organs, which is what makes an adult transplant reasonable at all.
• It accepts mixed chimerism, meaning donor and recipient marrow coexisting, and in sickle cell disease that is enough to stop the sickling.
• It requires long term immune suppression afterward, which is a real obligation and a real risk of its own.
• That series was small and selected, so its figures describe what is achievable in chosen patients and not what anybody is guaranteed by choosing it.

For an adult the question is rarely whether a transplant can be done, and almost always whether the organ damage already present makes the trade worse than it would have been at twelve. Put differently, an adult transplant runs a race against accumulated damage, and every year of waiting moves the finish line a little further away.

The donor problem, stated plainly

Everything above assumes a donor exists. For a large share of patients with this disease, one does not, and the reason behind that is not a medical one.

Two practical consequences follow. Typing siblings early costs little and settles the easiest question in the whole process. And a patient told that no donor exists should find out which searches were actually run, meaning siblings, the unrelated registries, cord blood banks and half matched family members, because those are four different searches and a negative on one is not a negative on all four. Four searches exist.

The half matched donor

Parents, children and half matched siblings share exactly half of the relevant tissue type, which for most of transplant history made them unusable. That has changed.

What a multicenter trial found

An international trial transplanted 70 evaluable participants with sickle cell disease using half matched family donors and a specific drug given after the graft to control the immune reaction. Two year event free survival came out at 82.6 percent and two year overall survival at 94.1 percent, while graft failure occurred in 8 of the 70, which is 11.4 percent, and every one of those was in a participant under 18. Five participants, 7.1 percent, died of infectious complications. So the approach works, it is measurably less reliable than a matched sibling, and it turns a patient with no donor into a patient with several. Access is the part that matters most here. Almost every patient has a parent, a child or a half matched sibling somewhere, and that single fact is the reason this approach changed the field. It also means a family told that no donor exists deserves to know whether this route was considered, since it is the newest of the four and the one most likely to have been left out.

Slide this table sideways on a small screen to reach the second column.

What the procedure costs

Every figure above has a matching figure that families are told less often, and a page arguing for honesty has to put them in the same place.

In the survey of 1,000 matched sibling transplants, 70 patients died, which is 7 percent of the series. In the half matched trial, 5 of 70 participants died of infection, which is 7.1 percent, while the adult nonmyeloablative series recorded no transplant related mortality at all in 30 carefully selected patients. Graft failure, meaning the transplant not taking, occurred in 23 of the 1,000 and in 8 of the 70. Those are the numbers to hold beside the survival figures, because in this disease the person consenting was not going to die this year, and a procedural mortality of several percent means something entirely different here from what it means in acute leukemia.

The other risks, in order of how much they change a life

Graft versus host disease, meaning the donor immune system attacking the recipient, which can be mild and can run chronic and disabling, then infection during the period with no immune function, which is what killed the five participants above. Graft failure, which returns the patient to the disease they started with and to a body that has been through conditioning for nothing. Infertility, covered further down. And the long tail of conditioning effects, which in a patient transplanted at eight years old runs for the rest of their life.

What a cure does not undo

Stopping the sickling stops new damage. It does not reverse the damage already done, and that distinction gets lost in the word cure.

One organ, followed afterward

Researchers followed 18 children and adolescents with sickle cell disease after a nonmyeloablative transplant and looked specifically at kidneys, where hyperfiltration, an early marker of sickle kidney injury, fell from 8 of the 18 before the transplant to 4 of 18 afterward, with a P value below 0.0001. Kidney function overall stayed stable. And long term hypertension after the transplant was present in 6 of the 18, which is 33.3 percent. The trajectory improved, the damage marker halved, and a third of these young patients still carried high blood pressure years later.

This table scrolls sideways on a phone. Drag it across to reach the second column.

Fertility, and the conversation that has to come first

Most people facing this decision are young. Conditioning damages the ovaries and the testes, and the window for doing anything about that closes well before the treatment starts. The clearest published figures come from thalassemia rather than sickle cell disease, which needs stating rather than hiding. A study evaluated 32 thalassemia major patients a median of 67 months after a myeloablative transplant. Ovarian failure was present in all 10 of the 10 girls evaluable for puberty, every one of whom needed hormone replacement, while three of 10 boys had gonadal impairment and 8 of the 10 went through spontaneous puberty. The conditioning regimens overlap heavily between the two diseases, so those numbers are the closest honest guide available, and they say that girls given myeloablative conditioning should expect ovarian failure. Saying so plainly is kinder than the alternative. A family told afterward that nobody raised it has lost something they would have acted on, and the referral takes one phone call made at the right moment.

This table scrolls sideways on a phone. Drag it across to reach the second column.

Gene therapy, and what it changes

Another route to the same destination has arrived, and it removes the donor from the equation entirely. One approach collects the patient own stem cells, edits them outside the body to restart production of fetal hemoglobin, and returns them after conditioning. A trial gave this to 44 patients. Among the 30 with enough follow up, 29 of them, which is 97 percent with a confidence interval of 83 to 100 percent, were free of severe vaso-occlusive crises for at least twelve consecutive months. All 30, which is 100 percent with a confidence interval of 88 to 100 percent, avoided hospitalization for a crisis over the same period. No donor was needed, no graft versus host disease was possible, and no immune suppression was required afterward at all. Read that list of absences carefully. No donor, no graft versus host disease, no immune suppression, which between them account for a large share of what makes an allogeneic transplant frightening.

Three things temper that. The conditioning is the same myeloablative chemotherapy, so the fertility risk and the immediate toxicity do not go away. Follow up is measured in a few years rather than decades, so nobody can yet say what a lifetime after gene editing looks like, and availability is narrow and expensive in a disease whose burden falls heaviest where health systems are least able to pay for it, which is a problem nobody has solved.

Who this is actually for

Nobody transplants mild disease. The recommendation follows severity, and severity in sickle cell disease has a reasonably concrete definition.

The features that push toward a transplant are recognizable. A stroke that has already happened, or an abnormal transcranial Doppler result that keeps recurring despite treatment. Repeated acute chest syndrome. Frequent pain crises that continue on hydroxyurea, or an inability to tolerate it. Transfusion dependence with iron loading that chelation is not controlling, along with red cell antibodies that make finding compatible blood progressively harder. And organ damage that is measurably advancing rather than static. A patient with none of those, whose disease is controlled on a tablet and who spends no time in hospital, is a patient in whom a procedure carrying several percent mortality is difficult to justify today.

Severity also has a timing element that argues in one direction, since the trade improves the earlier it is taken, because a child with less accumulated damage tolerates conditioning better and has more life left to gain. It worsens with every year of organ injury.

Saying that to the parents of a well eight year old is uncomfortable, and it remains true.

Children against adults, and the timing problem

A child transplanted at eight and an adult transplanted at thirty are having different procedures with different arithmetic behind them. Children tolerate conditioning better, carry less organ damage into it, and have more years to gain from stopping the disease, and they also have no say in the decision, and the fertility loss they may face was decided for them before they could be asked. Adults bring the opposite set. They can consent properly, they usually know exactly what the disease has cost them, and they arrive with kidneys, lungs and hips that have already absorbed twenty or thirty years of sickling, so the gentler adult regimens exist and an adult transplant becomes a different conversation rather than a delayed version of the same one. Neither group is choosing between a good option and a bad one. They are choosing between two different distributions of risk across two different amounts of remaining life, which is a harder thing to sit with and a more accurate description of it.

One practical consequence for families, which is that if a sibling might be a match, you should type them while the affected child is young, because that result changes what the next decade of decisions looks like and it costs a blood test.

One blood test. Worst of all is the version decided at twenty five, after the damage, because nobody typed the family at five.

Doing this from another country

Sickle cell disease travels better than an acute leukemia does, because the timeline has room in it and the first step is a search before any treatment begins.

Five things decide whether a plan can be made from a distance. The tissue typing, meaning the patient own HLA type and the type of every sibling, since that settles the easiest question before anything else. The disease record, meaning how many crises, how many admissions, how many chest episodes, and what happened on hydroxyurea. The organ assessment, meaning kidney function, an echocardiogram, lung function, liver imaging with an iron measurement, and a brain scan with transcranial Doppler results in a child. The transfusion history, including red cell antibodies, because those make finding compatible blood harder and they matter during the transplant itself. And the current medication list. Send those five and a written opinion can be produced without anybody boarding an aircraft.

Timing has genuine flexibility. The donor search runs while the patient stays at home on their usual treatment, the workup takes a few weeks, and only the transplant itself requires being here. Plan around three months for that portion, covering the workup, the admission of roughly four to six weeks, and enough recovery before a flight home, with the nights around the hospital stay spent in accommodation near the building. Once you are back home, the monitoring continues for years and most of it can be done locally with the plan written out for your own hematologist. Two documents make the arrangement work. A summary from your current hematologist covering the disease history, the transfusion record and the antibodies, and the tissue typing results for the whole family. Both take days to gather at home and weeks to chase from a distance. Start them early.

What drives the cost

No figure appears on this page, because the total follows which donor route applies and how the admission goes. What can be set out is which elements move it. The donor route is the largest single factor, since a matched sibling costs nothing to find while an unrelated registry donor carries a search and procurement charge and a cord blood unit carries a purchase price. Conditioning intensity comes next, because a myeloablative regimen means a longer and more complicated admission than a nonmyeloablative one. Then the length of stay itself, which runs roughly four to six weeks and extends when infection complicates the period with no immune function. Transfusion volume, antibiotic and antifungal courses, and the immune suppressing drugs taken for months afterward all accumulate, while iron chelation may continue after the transplant, since the iron already loaded does not leave when the disease does. Follow up runs for years of blood tests and organ imaging, with no fixed number of visits.

Find out which donor route the estimate assumes, how many inpatient days it covers, and what happens to the figure if a second search becomes necessary. Three questions.

What to ask

Six questions separate a unit that has thought about this disease from one that transplants leukemia and is willing to try.

Slide this table sideways on a small screen to reach the second column.

The question underneath the others

Ask what would have to be true for the unit to advise against a transplant in this particular patient, because a team that can name those conditions has weighed the trade described at the top of this page. A team that treats the answer as obvious has not.

What we arrange

For a decision this size, taken by a family who is usually not in crisis, the arrangements around it are part of thinking clearly.

A free written opinion on your records, your tissue typing and your organ assessment, returned in a language you read, before anything is booked. Sibling typing organized and interpreted, since that single result settles more than any other. One coordinator from the first message through to discharge and afterward, with a name and a direct number. Seven languages covered directly by the international patients team, namely English, Arabic, French, Russian, Serbian, Romanian and Spanish, with a professional interpreter arranged for anything else. A companion bed in the room for the whole admission, and accommodation nearby for the rest of the family. Airport transfers and transport between the accommodation and the hospital. Halal, vegetarian and diabetic meals from the hospital kitchen, and a prayer room in the building. A request for a female physician put to the department and met wherever the rota allows. An invitation letter naming the hospital and the treating doctor for the visa application, and a further letter when the stay runs past it. And once you are back home, the same coordinator on the same WhatsApp number, with the follow up plan written out for your local hematologist.

Send the file first. Nothing else needs deciding until the written opinion is in front of you.

Questions we are asked, a sickle cell transplant FAQ

References

1. Gluckman E, Cappelli B, Bernaudin F, et al. Sickle cell disease, an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood. 2017;129(11):1548-1556.
2. Bernaudin F, Socie G, Kuentz M, et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood. 2007;110(7):2749-2756.
3. Hsieh MM, Fitzhugh CD, Weitzel RP, et al. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. JAMA. 2014;312(1):48-56.
4. Kassim AA, de la Fuente J, Nur E, et al. An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease. Blood. 2024;143(25):2654-2665.
5. Gragert L, Eapen M, Williams E, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med. 2014;371(4):339-348.
6. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 1995;332(20):1317-1322.
7. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease, life expectancy and risk factors for early death. N Engl J Med. 1994;330(23):1639-1644.
8. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339(1):5-11.
9. Adamkiewicz TV, Abboud MR, Paley C, et al. Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury. Blood. 2009;114(21):4632-4638.
10. Li CK, Chik KW, Wong GWK, et al. Growth and endocrine function following bone marrow transplantation for thalassemia major. Pediatr Hematol Oncol. 2004;21(5):411-419.
11. Frangoul H, Locatelli F, Sharma A, et al. Exagamglogene autotemcel for severe sickle cell disease. N Engl J Med. 2024;390(18):1649-1662.
12. Pedersen SJV, Monagel DA, Mammen C, et al. Stable renal function in children and adolescents with sickle cell disease after nonmyeloablative hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2020;67(9):e28568.